Champignon Brands Inc is making a scientific case for psychedelic medicine

First mover in the red-hot psychedelic medicine field
Pioneering the use of psychedelics to treat mental health and addiction disorders
Strong portfolio of research into psychedelics complements ongoing clinical trials
Planning to open a network of ketamine clinics throughout North America by the end of 2020

What Champignon Brands does:

Champignon Brands Inc (CSE:SHRM) (OTCMKTS:SHRMF) is quickly emerging as a leader in the burgeoning field of psychedelic medicine.

The company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders.

As one of the first psychedelic companies to go public, the firm’s network of ketamine clinics complements its sharp focus on research and development.

Its strategic approach establishes a differentiated platform with operating treatment clinics in the US and Canada that also facilitate research and development of a wide range of therapeutic and medical applications of psilocybin, the psychoactive ingredient in mushrooms.

Champignon plans to advance its pursuit of treatments underpinned by psychedelic substances through clinical trials and assembling a compelling IP portfolio, clinical pipeline and drug development platform in the psychedelics space.

It owns 75% of the Canadian Rapid Treatment Centre of Excellence (CRTCE), a fully operational ketamine clinic in Mississauga, Ontario and the only clinic in the country approved by Health Canada to perform psilocybin doses.

Led by CEO Dr Roger McIntyre, a widely recognized expert in the study and treatment of mood disorders, Champignon is blazing a trail in an exciting new industry.

How is it doing:

It’s been a busy few months since Champignon’s shares debuted on the Canadian Securities Exchange in February, 2020.

The Vancouver-based company acquired ketamine clinic operator AltMed Capital Corp in an all-share deal that will see the two companies launch a network of subspecialty therapeutic clinics across the US.

The deal also gives Champignon a suite of intellectual property and research and development initiatives developed by its CEO, Dr McIntyre, one of AltMed’s founders. AltMed’s portfolio of assets will enable Champignon to reach the consumer directly via rapid onset medical treatments.

The CRTCE plans to expand its clinical footprint by establishing new clinics for ketamine, psilocybin and MDMA, as well as pursue partnerships with the broader pharmaceutical industry.

Champignon now has three trials in the Phase I stage and three trials in the preclinical stage, as well as seven patents for its ketamine/psilocybin delivery platforms and formulations. It also has a preferred commercial relationship with InterVivo Solutions, Canada’s largest neuroscience-focused preclinical contract research organization, to collaborate on Phase I testing and novel drug development of psychedelic molecules and delivery systems.

Just after it closed a C$15 million bought deal offering in June to fund its North American clinical expansion, Champignon announced it was revamping its brand identity to better reflect its scientific focus. The company is proposing changing its name to Apotheosis Scientific Ltd.

Inflection points:

Champignon is planning to roll out five unique ketamine clinics across Florida, California and the US Eastern Seaboard
Additional ketamine clinics are projected to be fully operational by the fourth quarter of 2020
The company is also planning to spin out its consumer packaged goods segment by the end of 3Q

What the boss says:

After releasing details of its corporate revamp, Champignon CEO Roger McIntyre told shareholders: “While the topic of medical psychedelics has recently gained worldwide momentum, I am exceptionally pleased with the strategic approach our team has taken in establishing a differentiated platform with operating treatment clinics in the US and Canada that also facilitate research and development of a wide range of therapeutic and medical applications."

“We have made tremendous progress to date and have proven our ability to quickly seize opportunities in this rapidly emerging industry. Looking forward to the second half of 2020, we will continue to work towards entering new markets and delivering new and innovative solutions throughout North America,” he added.